Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 3/20 | 0.40 |
| ▸ | FNTB | P49356 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760253 | 0.85 | FNTA (0.49) | HDAC6FNTAFNTBCXCR4 | |
| SCHEMBL30096647 | 0.78 | HDAC1 (0.49) | HDAC1HDAC6ADORA2AP2RX7 | |
| SCHEMBL4882174 | 0.78 | HDAC1 (0.49) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL18157989 | 0.76 | HDAC1 (0.52) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL14130906 | 0.76 | HDAC1 (0.44) | HDAC1HDAC6FNTAFNTBCXCR4 | |
| SCHEMBL21383597 | 0.76 | HDAC1 (0.48) | HDAC1HDAC6FNTAFNTBADORA2A | |
| SCHEMBL21383595 | 0.76 | HDAC1 (0.48) | HDAC1HDAC6FNTAFNTBADORA2A | |
| SCHEMBL2084608 | 0.74 | FNTA (0.51) | HDAC1HDAC6FNTAFNTBCXCR4 | |
| Oxalic Acid SCHEMBL3743488 | 0.74 | HDAC1 (0.53) | HDAC1HDAC6ADORA2AP2RX7CXCR4 | |
| SCHEMBL20483459 | 0.72 | HDAC1 (0.49) | HDAC1HDAC6CXCR4PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | HDAC1 1094/4885HDAC6 1371/4885FNTA 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.